The effect of topical cyclosporine in lichen planus of the hair

Comparison of the efficacy of topical cyclosporine versus clobetasol lotion in patients with lichen planopilaris (LPP) treated with hydroxychloroquine: a single-blinded randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170809035597N3

Enrollment

Registered

2022-11-19

Start date

2022-11-26

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lichen planopilaris. Lichen planopilaris

Interventions

Intervention 1: Intervention group 1: Topical cyclosporine 2.5% once a day for 5 months. Intervention 2: Intervention group 2: clobetasol lotion 0.05% once a day for 5 months.

Eligibility

Sex/Gender

All

Age

13 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients between 13 and 60 years of age histopathologic diagnosis of lichen planopilaris

Exclusion criteria

Exclusion criteria: Topical or oral treatment in the last month The presence of serious concomitant diseases such as uncontrolled diabetes, uncontrolled hypertension, malignancies, retinal diseases

Design outcomes

Primary

Measure	Time frame
Disease severity. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: based on LPPAI (lichen planopilaris activity index) criteria.	—

Secondary

Measure	Time frame
Physician satisfaction. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Based on the 5-point physician global assessment score using clinical and dermatoscopic images.;Patient satisfaction. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Based on the 5-point patient global assessment score.;Tolerability. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Using a checklist (yes, no).;Adverse effects. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Using a checklist.	—

Measure

Time frame

Physician satisfaction. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Based on the 5-point physician global assessment score using clinical and dermatoscopic images.;Patient satisfaction. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Based on the 5-point patient global assessment score.;Tolerability. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Using a checklist (yes, no).;Adverse effects. Timepoint: One, three, five and six months after the start of treatment. Method of measurement: Using a checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Goodarzi

Iran University of Medical Sciences

goodarzi.a@iums.ac.ir+98 21 6651 7341

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026